VALLEY COTTAGE, New York, June 11 XTLBiopharmaceuticals Ltd. (Nasdaq: XTLB; TASE: XTL) today announced a noticeconvening its Annual General Meeting ("AGM") and Extraordinary General Meeting("EGM"). The AGM and EGM will take place at the Conference Room at theCompany's Israeli offices at Building 3, Kiryat Weizmann Science Park, Rehovot,Israel 76100, at 4:00 p.m. Israel time, and 4:30 p.m. Israel time,respectively, on July 17, 2008.
The Notice of the AGM and EGM is available for the public at the USSecurities Exchange Edgar site: http://www.sec.gov/ and at the IsraelSecurities Authority's site: www.magna.isa.gov.il .
ABOUT XTL BIOPHARMACEUTICALS LTD.
XTL Biopharmaceuticals Ltd. ("XTL") is engaged in the development oftherapeutics for the treatment of diabetic neuropathic pain and HCV. XTL isdeveloping Bicifadine, a serotonin and norepinephrine reuptake inhibitor, forthe treatment of diabetic neuropathic pain, which is currently in a Phase 2bstudy. XTL has out-licensed its novel pre-clinical HCV small moleculeinhibitor program. XTL also has an active in-licensing and acquisition programdesigned to identify and acquire additional drug candidates. XTL is publiclytraded on the NASDAQ and Tel-Aviv Stock Exchanges (Nasdaq: XTLB; TASE: XTL).At the AGM it is proposed that: -- the annual report and financial statements for the year ended December 31, 2007 be received; -- Kesselman & Kesselman (PricewaterhouseCoopers) be reappointed as the Company's auditors and the fixing of their remuneration be authorized; and -- Messrs Michael Weiss, Ben Zion Weiner, William Kennedy, and Laurence Charney be re-appointed as Directors of the Company. At the EGM it is proposed that: -- the grant of options to Michael Weiss and Ben-Zion Weiner as detailed in the Notice be approved; -- the grant of options to Ben-Zion Weiner and William Kennedy as detailed in the Notice be approved; and -- the remuneration terms for Laurence Charney as detailed in the Notice be approved.
SOURCE XTL Biopharmaceuticals Ltd.